Atlas Trials

Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation

Clinical trial NCT05460195 · UNKNOWN

Trial details

NCT number
NCT05460195
Sponsor
Shanghai Chest Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Non-small Cell Lung CancerMinimal Residual DiseaseImmunotherapyAnti-angiogenesis
Start date
2022-01-01
Primary completion
2024-09-30
Enrollment
42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.